Methods for Brain Atrophy MR Quantification in Multiple Sclerosis: Application to the Multicenter INNI Dataset.
Italian Neuroimaging Network Initiative
atrophy pipelines
brain atrophy
multiple sclerosis
Journal
Journal of magnetic resonance imaging : JMRI
ISSN: 1522-2586
Titre abrégé: J Magn Reson Imaging
Pays: United States
ID NLM: 9105850
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
revised:
11
01
2023
received:
21
11
2022
accepted:
12
01
2023
medline:
18
9
2023
pubmed:
21
1
2023
entrez:
20
1
2023
Statut:
ppublish
Résumé
Current therapeutic strategies in multiple sclerosis (MS) target neurodegeneration. However, the integration of atrophy measures into the clinical scenario is still an unmet need. To compare methods for whole-brain and gray matter (GM) atrophy measurements using the Italian Neuroimaging Network Initiative (INNI) dataset. Retrospective (data available from INNI). A total of 466 patients with relapsing-remitting MS (mean age = 37.3 ± 10 years, 323 women) and 279 healthy controls (HC; mean age = 38.2 ± 13 years, 164 women). A 3.0-T, T1-weighted (spin echo and gradient echo without gadolinium injection) and T2-weighted spin echo scans at baseline and after 1 year (170 MS, 48 HC). Structural Image Evaluation using Normalization of Atrophy (SIENA-X/XL; version 5.0.9), Statistical Parametric Mapping (SPM-v12); and Jim-v8 (Xinapse Systems, Colchester, UK) software were applied to all subjects. In MS and HC, we evaluated the intraclass correlation coefficient (ICC) among FSL-SIENA(XL), SPM-v12, and Jim-v8 for cross-sectional whole-brain and GM tissue volumes and their longitudinal changes, the effect size according to the Cohen's d at baseline and the sample size requirement for whole-brain and GM atrophy progression at different power levels (lowest = 0.7, 0.05 alpha level). False discovery rate (Benjamini-Hochberg procedure) correction was applied. A P value <0.05 was considered statistically significant. SPM-v12 and Jim-v8 showed significant agreement for cross-sectional whole-brain (ICC = 0.93 for HC and ICC = 0.84 for MS) and GM volumes (ICC = 0.66 for HC and ICC = 0.90) and longitudinal assessment of GM atrophy (ICC = 0.35 for HC and ICC = 0.59 for MS), while no significant agreement was found in the comparisons between whole-brain and GM volumes for SIENA-X/XL and both SPM-v12 (P = 0.19 and P = 0.29, respectively) and Jim-v8 (P = 0.21 and P = 0.32, respectively). SPM-v12 and Jim-v8 showed the highest effect size for cross-sectional GM atrophy (Cohen's d = -0.63 and -0.61). Jim-v8 and SIENA(XL) showed the smallest sample size requirements for whole-brain (58) and GM atrophy (152), at 0.7 power level. The findings obtained in this study should be considered when selecting the appropriate brain atrophy pipeline for MS studies. 4. Stage 1.
Sections du résumé
BACKGROUND
Current therapeutic strategies in multiple sclerosis (MS) target neurodegeneration. However, the integration of atrophy measures into the clinical scenario is still an unmet need.
PURPOSE
To compare methods for whole-brain and gray matter (GM) atrophy measurements using the Italian Neuroimaging Network Initiative (INNI) dataset.
STUDY TYPE
Retrospective (data available from INNI).
POPULATION
A total of 466 patients with relapsing-remitting MS (mean age = 37.3 ± 10 years, 323 women) and 279 healthy controls (HC; mean age = 38.2 ± 13 years, 164 women).
FIELD STRENGTH/SEQUENCE
A 3.0-T, T1-weighted (spin echo and gradient echo without gadolinium injection) and T2-weighted spin echo scans at baseline and after 1 year (170 MS, 48 HC).
ASSESSMENT
Structural Image Evaluation using Normalization of Atrophy (SIENA-X/XL; version 5.0.9), Statistical Parametric Mapping (SPM-v12); and Jim-v8 (Xinapse Systems, Colchester, UK) software were applied to all subjects.
STATISTICAL TESTS
In MS and HC, we evaluated the intraclass correlation coefficient (ICC) among FSL-SIENA(XL), SPM-v12, and Jim-v8 for cross-sectional whole-brain and GM tissue volumes and their longitudinal changes, the effect size according to the Cohen's d at baseline and the sample size requirement for whole-brain and GM atrophy progression at different power levels (lowest = 0.7, 0.05 alpha level). False discovery rate (Benjamini-Hochberg procedure) correction was applied. A P value <0.05 was considered statistically significant.
RESULTS
SPM-v12 and Jim-v8 showed significant agreement for cross-sectional whole-brain (ICC = 0.93 for HC and ICC = 0.84 for MS) and GM volumes (ICC = 0.66 for HC and ICC = 0.90) and longitudinal assessment of GM atrophy (ICC = 0.35 for HC and ICC = 0.59 for MS), while no significant agreement was found in the comparisons between whole-brain and GM volumes for SIENA-X/XL and both SPM-v12 (P = 0.19 and P = 0.29, respectively) and Jim-v8 (P = 0.21 and P = 0.32, respectively). SPM-v12 and Jim-v8 showed the highest effect size for cross-sectional GM atrophy (Cohen's d = -0.63 and -0.61). Jim-v8 and SIENA(XL) showed the smallest sample size requirements for whole-brain (58) and GM atrophy (152), at 0.7 power level.
DATA CONCLUSION
The findings obtained in this study should be considered when selecting the appropriate brain atrophy pipeline for MS studies.
EVIDENCE LEVEL
4.
TECHNICAL EFFICACY
Stage 1.
Types de publication
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1221-1231Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2023 The Authors. Journal of Magnetic Resonance Imaging published by Wiley Periodicals LLC on behalf of International Society for Magnetic Resonance in Medicine.
Références
Filippi M, Bar-Or A, Piehl F, et al. Multiple sclerosis. Nat Rev Dis Primers 2018;4(1):43.
Rocca MA, Battaglini M, Benedict RH, et al. Brain MRI atrophy quantification in MS: From methods to clinical application. Neurology 2017;88(4):403-413.
Damjanovic D, Valsasina P, Rocca MA, et al. Hippocampal and deep gray matter nuclei atrophy is relevant for explaining cognitive impairment in MS: A multicenter study. AJNR Am J Neuroradiol 2017;38(1):18-24.
De Stefano N, Matthews PM, Filippi M, et al. Evidence of early cortical atrophy in MS: Relevance to white matter changes and disability. Neurology 2003;60(7):1157-1162.
Fisher E, Lee JC, Nakamura K, Rudick RA. Gray matter atrophy in multiple sclerosis: A longitudinal study. Ann Neurol 2008;64(3):255-265.
Kappos L, De Stefano N, Freedman MS, et al. Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing-remitting multiple sclerosis. Mult Scler 2016;22(10):1297-1305.
Allanach JR, Farrell JW, Mesidor M, Karimi-Abdolrezaee S. Current status of neuroprotective and neuroregenerative strategies in multiple sclerosis: A systematic review. Mult Scler 2022;28(1):29-48.
Sormani MP, Arnold DL, De Stefano N. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol 2013;75:43-49.
Vidal-Jordana A, Sastre-Garriga J, Rovira A, Montalban X. Treating relapsing-remitting multiple sclerosis: Therapy effects on brain atrophy. J Neurol 2015;262(12):2617-2626.
Sastre-Garriga J, Pareto D, Battaglini M, et al. MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. Nat Rev Neurol 2020;16(3):171-182.
Storelli L, Rocca MA, Pagani E, et al. Measurement of whole-brain and gray matter atrophy in multiple sclerosis: Assessment with MR imaging. Radiology 2018;288(2):554-564.
Beadnall HN, Wang C, Van Hecke W, Ribbens A, Billiet T, Barnett MH. Comparing longitudinal brain atrophy measurement techniques in a real-world multiple sclerosis clinical practice cohort: Towards clinical integration? Ther Adv Neurol Disord 2019;12:1756286418823462.
Grassiot B, Desgranges B, Eustache F, Defer G. Quantification and clinical relevance of brain atrophy in multiple sclerosis: A review. J Neurol 2009;256(9):1397-1412.
Steenwijk MD, Amiri H, Schoonheim MM, et al. Agreement of MSmetrix with established methods for measuring cross-sectional and longitudinal brain atrophy. Neuroimage Clin 2017;15:843-853.
Vrenken H, Jenkinson M, Horsfield MA, et al. Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis. J Neurol 2013;260(10):2458-2471.
Derakhshan M, Caramanos Z, Giacomini PS, et al. Evaluation of automated techniques for the quantification of grey matter atrophy in patients with multiple sclerosis. Neuroimage 2010;52(4):1261-1267.
Ge Y, Grossman RI, Udupa JK, Babb JS, Nyul LG, Kolson DL. Brain atrophy in relapsing-remitting multiple sclerosis: Fractional volumetric analysis of gray matter and white matter. Radiology 2001;220(3):606-610.
Kazemi K, Noorizadeh N. Quantitative comparison of SPM, FSL, and Brainsuite for brain MR image segmentation. J Biomed Phys Eng 2014;4(1):13-26.
Sanfilipo MP, Benedict RH, Weinstock-Guttman B, Bakshi R. Gray and white matter brain atrophy and neuropsychological impairment in multiple sclerosis. Neurology 2006;66(5):685-692.
Filippi M, Tedeschi G, Pantano P, et al. The Italian neuroimaging network initiative (INNI): Enabling the use of advanced MRI techniques in patients with MS. Neurol Sci 2017;38(6):1029-1038.
Lublin FD, Reingold SC. Defining the clinical course ofmultiple sclerosis: Results of an international survey. National Multiple sclerosis society (USA) advisory committee on clinical trials of new agents in multiple sclerosis. Neurology 1996;46:907-911.
Storelli L, Rocca MA, Pantano P, et al. MRI quality control for the Italian neuroimaging network initiative: Moving towards big data in multiple sclerosis. J Neurol 2019;266(11):2848-2858.
Filippi M, Preziosa P, Banwell BL, et al. Assessment of lesions on magnetic resonance imaging in multiple sclerosis: Practical guidelines. Brain 2019;142(7):1858-1875.
Battaglini M, Jenkinson M, De Stefano N. Evaluating and reducing the impact of white matter lesions on brain volume measurements. Hum Brain Mapp 2011;33:2062-2071.
Battaglini M, Jenkinson M, De Stefano N, Alzheimer's Disease Neuroimaging I. SIENA-XL for improving the assessment of gray and white matter volume changes on brain MRI. Hum Brain Mapp 2018;39(3):1063-1077.
http://www.xinapse.com/Manual/brain_atrophy_intro.html
FSL-FMRIB. https://fsl.fmrib.ox.ac.uk/fsl/fslwiki
https://www.fil.ion.ucl.ac.uk/spm/software/spm12/
Cohen J. Statistical power analysis for the behavioral sciences (2nd ed). Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
Mazziotta J, Toga A, Evans A, et al. A probabilistic atlas and reference system for the human brain: International consortium for brain mapping (ICBM). Philos Trans R Soc Lond B Biol Sci 2001;356(1412):1293-1322.
Ashburner J, Friston KJ. Unified segmentation. Neuroimage 2005;26(3):839-851.
Zhang Y, Brady M, Smith S. Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Trans Med Imaging 2001;20(1):45-57.
De Stefano N, Battaglini M, Pareto D, et al. MAGNIMS recommendations for harmonization of MRI data in MS multicenter studies. Neuroimage Clin. 2022;34:102972.
Wattjes MP, Ciccarelli O, Reich DS, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol 2021;20(8):653-670.
Amiri H, de Sitter A, Bendfeldt K, et al. Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI. NeuroImage 2018;19:466-475.
De Stefano N, Giorgio A, Battaglini M, et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology 2010;74(23):1868-1876.
Nakamura K, Guizard N, Fonov VS, Narayanan S, Collins DL, Arnold DL. Jacobian integration method increases the statistical power to measure gray matter atrophy in multiple sclerosis. Neuroimage Clin. 2014;4:10-17.
Battaglini M, Gentile G, Luchetti L, et al. Lifespan normative data on rates of brain volume changes. Neurobiol Aging 2019;81:30-37.